206 related articles for article (PubMed ID: 21057205)
21. Sequential combination of flavopiridol and docetaxel reduces the levels of X-linked inhibitor of apoptosis and AKT proteins and stimulates apoptosis in human LNCaP prostate cancer cells.
Gomez LA; de Las Pozas A; Perez-Stable C
Mol Cancer Ther; 2006 May; 5(5):1216-26. PubMed ID: 16731754
[TBL] [Abstract][Full Text] [Related]
22. Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin.
Hadaschik BA; Ettinger S; Sowery RD; Zoubeidi A; Andersen RJ; Roberge M; Gleave ME
Int J Cancer; 2008 May; 122(10):2368-76. PubMed ID: 18240145
[TBL] [Abstract][Full Text] [Related]
23. Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-kappaB.
Kim SM; Lee SY; Cho JS; Son SM; Choi SS; Yun YP; Yoo HS; Yoon DY; Oh KW; Han SB; Hong JT
Eur J Pharmacol; 2010 Apr; 631(1-3):1-9. PubMed ID: 20056115
[TBL] [Abstract][Full Text] [Related]
24. Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205.
Puhr M; Hoefer J; Schäfer G; Erb HH; Oh SJ; Klocker H; Heidegger I; Neuwirt H; Culig Z
Am J Pathol; 2012 Dec; 181(6):2188-201. PubMed ID: 23041061
[TBL] [Abstract][Full Text] [Related]
25. Enhancement of docetaxel-induced cytotoxicity and apoptosis by all-trans retinoic acid (ATRA) through downregulation of survivin (BIRC5), MCL-1 and LTbeta-R in hormone- and drug resistant prostate cancer cell line, DU-145.
Kucukzeybek Y; Gul MK; Cengiz E; Erten C; Karaca B; Gorumlu G; Atmaca H; Uzunoglu S; Karabulut B; Sanli UA; Uslu R
J Exp Clin Cancer Res; 2008 Sep; 27(1):37. PubMed ID: 18789152
[TBL] [Abstract][Full Text] [Related]
26. TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer.
Sekino Y; Han X; Kawaguchi T; Babasaki T; Goto K; Inoue S; Hayashi T; Teishima J; Shiota M; Yasui W; Matsubara A
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412591
[TBL] [Abstract][Full Text] [Related]
27. Interferon inducible antiviral MxA is inversely associated with prostate cancer and regulates cell cycle, invasion and Docetaxel induced apoptosis.
Brown SG; Knowell AE; Hunt A; Patel D; Bhosle S; Chaudhary J
Prostate; 2015 Feb; 75(3):266-79. PubMed ID: 25327819
[TBL] [Abstract][Full Text] [Related]
28. Zoledronic acid increases cytotoxicity by inducing apoptosis in hormone and docetaxel-resistant prostate cancer cell lines.
Varol U; Degirmenci M; Karaca B; Atmaca H; Kisim A; Uzunoglu S; Sezgin C; Sanli UA; Uslu R
Tumour Biol; 2015 Feb; 36(2):779-86. PubMed ID: 25293519
[TBL] [Abstract][Full Text] [Related]
29. Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor.
Shiota M; Kashiwagi E; Yokomizo A; Takeuchi A; Dejima T; Song Y; Tatsugami K; Inokuchi J; Uchiumi T; Naito S
Prostate; 2013 Sep; 73(12):1336-44. PubMed ID: 23775496
[TBL] [Abstract][Full Text] [Related]
30. Metabolic shift toward oxidative phosphorylation in docetaxel resistant prostate cancer cells.
Ippolito L; Marini A; Cavallini L; Morandi A; Pietrovito L; Pintus G; Giannoni E; Schrader T; Puhr M; Chiarugi P; Taddei ML
Oncotarget; 2016 Sep; 7(38):61890-61904. PubMed ID: 27542265
[TBL] [Abstract][Full Text] [Related]
31. Functional p53 determines docetaxel sensitivity in prostate cancer cells.
Liu C; Zhu Y; Lou W; Nadiminty N; Chen X; Zhou Q; Shi XB; deVere White RW; Gao AC
Prostate; 2013 Mar; 73(4):418-27. PubMed ID: 22996738
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic downregulation of RUNX3 by DNA methylation induces docetaxel chemoresistance in human lung adenocarcinoma cells by activation of the AKT pathway.
Zheng Y; Wang R; Song HZ; Pan BZ; Zhang YW; Chen LB
Int J Biochem Cell Biol; 2013 Nov; 45(11):2369-78. PubMed ID: 23892093
[TBL] [Abstract][Full Text] [Related]
33. Proteomic analysis of extracellular vesicles identified PI3K pathway as a potential therapeutic target for cabazitaxel-resistant prostate cancer.
Hishida S; Kawakami K; Fujita Y; Kato T; Takai M; Iinuma K; Nakane K; Tsuchiya T; Koie T; Miura Y; Ito M; Mizutani K
Prostate; 2021 Jun; 81(9):592-602. PubMed ID: 33905554
[TBL] [Abstract][Full Text] [Related]
34. Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.
Alshaker H; Wang Q; Kawano Y; Arafat T; Böhler T; Winkler M; Cooper C; Pchejetski D
Oncotarget; 2016 Dec; 7(49):80943-80956. PubMed ID: 27821815
[TBL] [Abstract][Full Text] [Related]
35. A mutation in beta-tubulin and a sustained dependence on androgen receptor signalling in a newly established docetaxel-resistant prostate cancer cell line.
Hara T; Ushio K; Nishiwaki M; Kouno J; Araki H; Hikichi Y; Hattori M; Imai Y; Yamaoka M
Cell Biol Int; 2010 Jan; 34(2):177-84. PubMed ID: 19947927
[TBL] [Abstract][Full Text] [Related]
36. Nuclear factor-kappa B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer.
Codony-Servat J; Marín-Aguilera M; Visa L; García-Albéniz X; Pineda E; Fernández PL; Filella X; Gascón P; Mellado B
Prostate; 2013 Apr; 73(5):512-21. PubMed ID: 23038213
[TBL] [Abstract][Full Text] [Related]
37. The role of testicular nuclear receptor 4 in chemo-resistance of docetaxel in castration-resistant prostate cancer.
Chen B; Yu S; Ding X; Jing C; Xia L; Wang M; Matro E; Rehman F; Niu Y; Li G; Chang C
Cancer Gene Ther; 2014 Oct; 21(10):411-5. PubMed ID: 25104727
[TBL] [Abstract][Full Text] [Related]
38. GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells.
Karanika S; Karantanos T; Kurosaka S; Wang J; Hirayama T; Yang G; Park S; Golstov AA; Tanimoto R; Li L; Thompson TC
Mol Cancer; 2015 Jun; 14():122. PubMed ID: 26084402
[TBL] [Abstract][Full Text] [Related]
39. Induction of clusterin by AKT--role in cytoprotection against docetaxel in prostate tumor cells.
Zhong B; Sallman DA; Gilvary DL; Pernazza D; Sahakian E; Fritz D; Cheng JQ; Trougakos I; Wei S; Djeu JY
Mol Cancer Ther; 2010 Jun; 9(6):1831-41. PubMed ID: 20501799
[TBL] [Abstract][Full Text] [Related]
40. Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling.
Zhao L; Lee BY; Brown DA; Molloy MP; Marx GM; Pavlakis N; Boyer MJ; Stockler MR; Kaplan W; Breit SN; Sutherland RL; Henshall SM; Horvath LG
Cancer Res; 2009 Oct; 69(19):7696-703. PubMed ID: 19773444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
